The signalling lymphocytic activation molecule family member 8 (SLAMF8)/CD353 is a member of the CD2 family of proteins. Its ligand has not been identified. SLAMF8 
| INTRODUC TI ON
Members of the signalling lymphocytic activation molecule (SLAM) family are transmembrane proteins that play both positive and negative roles in haematopoietic cells. [1, 2] Their signalling is mediated by SLAM-associated protein (SAP) or Ewing's sarcoma-associated transcript 2 (EAT-2) in T, NK, B and macrophage cells. [1, 2] SLAM family member 8 (SLAMF8)/B-lymphocyte activator, macrophage expressed/CD353 is a member of the SLAM family, [3] and negatively regulates human macrophage functions, [4, 5] although its ligand has not been identified. To the best of our knowledge, no report has evaluated SLAMF8 expression or function in other cell types such as mast cells.
Mast cells are descendants of haematopoietic stem cells, and are immunocompetent. [6] Activation of KIT (CD117) by its ligand, stem cell factor (SCF, Steel factor/KIT ligand), is critical in terms of the growth, development and survival of mast cells. [6] Mastocytosis reflects dysregulated mast cell proliferation. [7] Gain-of-function mutations in KIT, particularly D816V, cause human mastocytosis. [8, 9] Therefore, inhibition of KIT signalling would be useful when treating this neoplastic disorder. [10] A promising means to this end is stimulation or blocking of receptors expressed by human mastocytosis cells. [11] [12] [13] [14] [15] [16] [17] [18] [19] Another SLAM family member CD84 would be also a promising target to inhibit KIT signalling. CD84 expresses on human mast cells and inhibits FcεRI signalling on the cells, [20, 21] although it remains uncertain whether or not CD84 inhibits KIT signalling. Here, we hypothesized that SLAMF8 might regulate the activity of human mastocytosis cells, and showed that SLAMF8 was indeed expressed by such cells.
| ME THODS

| Patients
Nineteen patients diagnosed with mastocytosis at Kyoto University Hospital (Sakyo-ku, Kyoto, Japan) underwent skin biopsies after they signed the "Kyoto University Hospital Informed Consent Form for the Non-therapeutic Use of Histopathological Materials" [19] (summarized in Table 1 ). The signed forms were uploaded to the electronic health records. All patients were diagnosed based on the World Health Organization criteria.
| Cells
LAD2 cells were cultured in StemPro-34 medium (Invitrogen, Carlsbad, CA) containing recombinant human SCF (Peprotech, London, UK). [22] HMC1.2, K562, MOLT-4 and U937 cells were cultured in IMDM medium supplemented with 10% (v/v) FBS.
[23]
| SHP-2 inhibitor
The specific SHP-2 inhibitor PTP Inhibitor V, PHPS1, was purchased from Santa Cruz Biotechnology (San Diego, CA), and was used at a concentration of 10 μM in all experiments.
[24] 
| Immunohistochemistry
| RT-PCR
| Immunoblotting
Cells ( 
| SLAMF8 knock-down
| Cell growth assay
Control and SLAMF8-KD HMC1.2 or LAD2 cells were cultured for 
| Assessment of RAS-RAF interaction
We assessed the extent of RAS-RAF interaction using a Ras Activation ELISA Kit (Merck Millipore, Darmstadt, Germany). Control and SLAMF8-KD HMC1.2 cells (1-3 × 10 4 cells) were cultured for 24 h. After centrifugation, cell pellets were processed and subjected to ELISA according to the manufacturer's protocol.
| Colocation of SLAMF8 and SHP-2
The DuoLink In situ kit (Sigma Aldrich) was used to evaluate the colocation of SLAMF8 and SHP-2 according to the manufacturer's protocol. [25] We used an anti-SHP-2 antibody (goat polyclonal antibody, ab9214, Abcam) and an anti-SLAMF8 antibody (rabbit polyclonal antibody, bs-2473R; Bioss). We collected and centrifuged HMC1.2 cells and resuspended the cell pellets in 20%
(v/v) buffered formalin (pH 7.0) followed by centrifugation for 5 minutes at 24 g. Then, the cell pellets were dehydrated, embedded in paraffin and the paraffin blocks were cut into sections 3-4 μm thick prior to H&E staining and DuoLink evaluation.
In another experiment, pathological specimens of mastocytosis were similarly prepared for H&E staining, DuoLink evaluation and immunohistochemistry.
| Statistical analysis
Differences between groups were compared using Student's t test (Excel; Microsoft, Redmond, WA), and a P value < .05 was taken to indicate statistical significance. Data are expressed as means ± standard errors of the means (SEs).
| RE SULTS
| SLAMF8 interacts with SHP-2 in HMC1.2 cells and human neoplastic mast cells including pathological specimens
We immunohistochemically assessed SLAMF8 protein expression in human neoplastic mast cells (mastocytosis specimens Figure 1A ).
We also found that keratinocytes including the pathological specimens were also stained with the anti-SLAMF8 antibody (16 of 19 cases [84.2%]).
| Human neoplastic mast cell lines express SLAMF8, but not SAP or EAT-2
Next, we explored the expression levels of SLAMF8-encoding mRNA and the protein per se in the human neoplastic mast cell lines LAD2 and HMC1.2 using RT-PCR and immunoblotting, respectively. LAD2 cells express wild-type KIT protein [21] and HMC1.2 cells express mutated protein. [22] Both cell lines expressed SLAMF8-encoding mRNA and the protein ( Figures 1B,C) . We did not detect mRNAs encoding the adaptor proteins SAP and EAT-2 that transduce SLAM family signals ( Figure 1B ).
| SLAMF8 knock-down decreases KIT-mediated proliferation of HMC1.2 cells, but not LAD2 cells
No ligand for SLAMF8 has been identified. Therefore, we knocked down SLAMF8 in human mast cell lines to explore the function of the protein using shRNA targeting human SLAMF8. We employed the CCK-8 kit to assess the effects of knock-down on the growth of HMC1.2 and LAD2 cells. SLAMF8 knock-down reduced the mutated KIT-driven growth of HMC1.2 cells, but not SCF-dependent or SCFindependent growth of LAD2 cells (Figure 2A ).
| SLAMF8 knock-down of HMC1.2 cells reduces KIT-mediated RAS-RAF-ERK activation
We assessed the status of signalling molecules downstream of the mutated KIT of HMC1.2 cells via immunoblotting and ELISA. 
SHP-2 acts downstream of RAS-RAF-ERK in human mastocytosis
cells harbouring mutated KIT [26] [27] [28] and thus, we assessed the effects of SLAMF8 knock-down on the SHP-2 status of HMC1.2 cells.
Immunoblotting revealed that knock-down also reduced activation of SHP-2 ( Figure 2B ). We also confirmed that the SHP-2 inhibitor PHPS1 [24] suppressed the KIT-mediated ERK activation and proliferation of HMC1.2 cells, at levels equivalent to those afforded by SLMAF8 knock-down ( Figures 2D,E) .
| SLAMF8 interacts with SHP-2 in HMC1.2 cells and human neoplastic mast cells including pathological specimens
We investigated the potential interactions between SLAMF8 and SHP-2 in neoplastic mast cells using the DuoLink in situ kit. [25] SLAMF8 interacted with SHP-2 in HMC1.2 cells ( Figure 3A) . The
DuoLink method also revealed an interaction between SLAMF8
and SHP-2 in mastocytosis cells and keratinocytes of all specimens ( Figure 3B ). 
| D ISCUSS I ON
SLAMF8 suppresses human macrophage function. [4, 5] By contrast, SLAMF8 enhances the activity of human mast cells. We hypothesized that the difference was attributable to variation in the adaptor proteins of human macrophage and mast cells. We found that human macrophages expressed SAP and EAT-2, but human mast cells did not, in agreement with a previous report. [20] In macrophages, SAP and EAT-2 compromise the interaction between SHP-2 and other SLAM family proteins including CD150, CD229 and CD244. [29] Lack of SAP and EAT-2 allows SHP-2 and SLAMF8 to interact in human mast cells.
SHP-2 acts downstream of RAS-RAF-ERK in human neoplastic
mast cells with KIT mutations, [26] [27] [28] but under certain conditions, SHP-2 has negative functions in human mast cells. [15, 17] We found that SHP-2 seemed to play an oncogenic, KIT-activated RAS-RAF-ERK-associated role when interacting with SLAMF8. This suggests that SLAMF8 may be a useful target in oncogenic KIT-driven neoplastic mast cells, although to the best of our knowledge, no specific inhibitor of, or a blocking antibody targeting, SLAMF8 has yet been identified. We would expect that such drugs would not affect nonneoplastic mast cells expressing wild-type KIT, because we detected no effects of SLAMF8 knock-down in LAD2 cells.
Other SLAM family proteins (CD84, CD150, and CD244) use the Src family kinases LCK and FYN to transduce positive signals. [30, 31] Here, we compared the status of Src family kinases in mock knockdown and SLAMF8 knock-down HMC1.2 cells. We did not find any differences between the cells (data not shown), and thus conclude that Src family kinases are not involved in SLAMF8 signalling in HMC1.2 cells.
Here, immunohistochemistry and the Duo Link in situ method indicate the expression of SLAMF8 in keratinocytes of pathological specimens. We will further explore the function of SLAMF8 in keratinocytes.
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